Effectiveness and safety of chemotherapy for patients with malignant gastrointestinal obstruction: A Japanese population-based cohort study

Table 4 Subgroup analysis of the effect of chemotherapy after the intervention on overall survival and patency duration

Subgroups	Overall survival		Patency duration
	Adjusted HR (95%CI)	P value	Adjusted HR (95%CI)	P value
All patients	0.36 (0.28-0.46)	< 0.001	0.49 (0.41-0.59)	< 0.001
Age
Young (< 75 yr)	0.36 (0.27-0.48)	< 0.001	0.48 (0.39-0.60)	< 0.001
Elder (≥ 75 yr)	0.38 (0.24-0.61)	< 0.001	0.52 (0.35-0.76)	< 0.001
Charlson co-morbidity index
< 3	0.43 (0.27-0.68)	< 0.001	0.47 (0.33-0.67)	< 0.001
≥ 3	0.31 (0.23-0.41)	< 0.001	0.47 (0.37-0.59)	< 0.001
Barthel index
≥ 60	0.38 (0.29-0.50)	< 0.001	0.52 (0.42-0.64)	< 0.001
< 60	0.24 (0.11-0.54)	< 0.001	0.26 (0.13-0.51)	< 0.001
Cancer type
Esophageal cancer	0.45 (0.21-1.00)	0.049	0.80 (0.43-1.49)	0.479
Gastric cancer	0.38 (0.24-0.62)	< 0.001	0.62 (0.43-0.90)	0.012
Pancreatic cancer	0.14 (0.07-0.29)	< 0.001	0.28 (0.17-0.45)	< 0.001
Colorectal cancer	0.45 (0.25-0.78)	0.005	0.45 (0.29-0.70)	< 0.001
Obstruction site
Esophageal obstruction	0.46 (0.23-0.92)	0.028	0.80 (0.47-1.37)	0.425
Gastroduodenal obstruction	0.26 (0.18-0.39)	< 0.001	0.37 (0.28-0.50)	< 0.001
Lower gastrointestinal obstruction	0.44 (0.30-0.64)	< 0.001	0.51 (0.38-0.69)	< 0.001
Intervention type
Palliative surgery	0.34 (0.24-0.48)	< 0.001	0.39 (0.29-0.52)	< 0.001
SEMS placement	0.37 (0.26-0.52)	< 0.001	0.54 (0.42-0.70)	< 0.001

CI: Confidence interval; HR: Hazard ratio; SEMS: Self-expandable metal stent.